W. Jeffrey Allard
University of Texas MD Anderson Cancer Center
14 Papers
97 Citations
W. Jeffrey Allard is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Circulating tumor cell & Metastatic breast cancer. The author has an hindex of 13, co-authored 14 publications. Previous affiliations of W. Jeffrey Allard include University of Michigan.
Chat about Author
Papers
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
4.6K
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
2.5K
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Massimo Cristofanilli,Daniel F. Hayes,G. Thomas Budd,Mathew J. Ellis,A. Stopeck,James M. Reuben,Gerald V. Doyle,Jeri Matera,W. Jeffrey Allard,M. Craig Miller,Herbert A. Fritsche,Gabriel N. Hortobagyi,Leon W.M.M. Terstappen +12 more
TL;DR: In this article, the authors investigated whether the presence of circulating tumor cells (CTCs) predicts treatment efficacy, progression-free survival (PFS), and overall survival (OS) in patients with newly diagnosed metastatic breast cancer who were about to start first-line therapy.
1.1K
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
Daniel F. Hayes,Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,A. Stopeck,M. Craig Miller,Jeri Matera,W. Jeffrey Allard,Gerald V. Doyle,Leon W.W.M. Terstappen +9 more
TL;DR: In this paper, the authors reported that ≥5 circulating tumor cells (CTC) in 7.5 mL blood at baseline and at first follow-up in 177 patients with metastatic breast cancer (MBC) were associated with poor clinical outcome.
1K
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Richard G. Moore,D. Scott McMeekin,A.K. Brown,Paul DiSilvestro,M. Craig Miller,W. Jeffrey Allard,Walter H. Gajewski,Robert J. Kurman,Robert C. Bast,Steven J. Skates +9 more
TL;DR: An algorithm utilizing HE4 and CA125 successfully classified patients into high and low risk groups with 93.8% of EOC correctly classified as high risk, which can be used to effectively triage patients to centers of excellence.
858